SCHEMBL1115630

SCHEMBL1115630

O=C(O)Oc1c[nH]c2c(ccc3cccnc32)c1=O

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TET2 Q6N021 1/20 0.71
TET1 Q8NFU7 1/20 0.71
CSNK2A2 P19784 1/20 0.45
CSNK2B P67870 1/20 0.45
CSNK2A1 P68400 1/20 0.45
LMNA P02545 4/20 0.41
METAP2 P50579 1/20 0.41
METAP1 P53582 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
MAPT P10636 5/20 0.40
KDM4E B2RXH2 4/20 0.40
HSP90AA1 P07900 2/20 0.39
ALDH1A1 P00352 3/20 0.39
L3MBTL1 Q9Y468 2/20 0.38
HTT P42858 2/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
POLB P06746 2/20 0.37
HPGD P15428 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL703592 0.83 TET2 (1.00) TET2TET1CSNK2A2CSNK2BCSNK2A1
SCHEMBL22545416 0.82 TET2 (0.79) TET2TET1CSNK2A2CSNK2BCSNK2A1
SCHEMBL17237877 0.76 TET2 (0.69) TET2TET1CSNK2A2CSNK2BCSNK2A1
SCHEMBL18306013 0.76 ADORA2A (0.55) TET2TET1KMT2A
SCHEMBL13310738 0.76 TET2 (0.65) TET2TET1CSNK2A2CSNK2BCSNK2A1
SCHEMBL22545520 0.72 TET2 (0.66) TET2TET1CSNK2A2CSNK2BCSNK2A1
SCHEMBL3415803 0.72 LMNA (0.71) LMNAMETAP2METAP1HDAC6MAPT
SCHEMBL377229 0.71 LMNA (0.50) TET2TET1LMNAMETAP2METAP1
SCHEMBL7016593 0.71 TET2 (0.55) TET2TET1LMNAMAPTKDM4E
SCHEMBL22545420 0.71 TET2 (0.64) TET2TET1CSNK2A2CSNK2BCSNK2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1919463-B9 USE OF HIF 1ALFA MODULATORS FOR TREATMENT OF CANCER FIBROGEN INC (US) 2011-02-02 EP claimed
EP-1919463-B1 USE OF HIF 1ALFA MODULATORS FOR TREATMENT OF CANCER FIBROGEN INC (US) 2010-06-09 EP claimed